Related Experiment Video
Updated: Aug 13, 2026
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 12, 2014
[Detection of P-glycoprotein in squamous cell carcinoma of larynx]
Abstract:
The multidrug resistance (MDR) of malignant tumor is a troublesome problem in the chemotherapy. One established mechanism of multidrug resistance is elevated expression of the P-glycoprotein (PGP). JSB1 (which is a special monoclonal antibody of human MDR, PGP) was used to examine the expression of PGP by immunohistochemistry in 23 specimens of squamous cell carcinoma of larynx. The expression of JSB1 in 10 normal laryngeal tissue specimens was also studied, no positive result was found. Of the 23 laryngeal cancer specimens, positive reaction to JSB1 was showed in 15, and there was no relationship between the positive expression, and the tumor differentiation, T staging and lymph-node metastasis. However, by using another newly developed monoclonal antibody C219, a different result was obtained from specimens of the same patients.
Insights
Multidrug resistance in cancer is often linked to P-glycoprotein (PGP). This study examined PGP expression in laryngeal cancer using JSB1 antibody, finding it in 15 of 23 tumors, but C219 antibody yielded different results.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- Multidrug resistance (MDR) in malignant tumors poses a significant challenge in chemotherapy.
- Elevated expression of P-glycoprotein (PGP) is a key mechanism contributing to MDR.
- Investigating PGP expression is crucial for understanding and potentially overcoming treatment resistance.
Purpose of the Study:
- To evaluate the expression of PGP in laryngeal squamous cell carcinoma using the JSB1 monoclonal antibody.
- To compare the findings with normal laryngeal tissues.
- To assess the correlation between PGP expression and clinicopathological features.
Main Methods:
- Immunohistochemistry was employed to detect PGP expression.
- JSB1 monoclonal antibody was used on 23 laryngeal cancer specimens and 10 normal laryngeal tissues.
- Clinicopathological data including tumor differentiation, T staging, and lymph-node metastasis were analyzed.
Main Results:
- No PGP expression was detected in the 10 normal laryngeal tissue specimens.
- Positive JSB1 staining was observed in 15 out of 23 (65.2%) laryngeal cancer specimens.
- No significant correlation was found between JSB1-positive PGP expression and tumor differentiation, T staging, or lymph-node metastasis.
- A different outcome was noted when using the C219 monoclonal antibody on the same patient specimens.
Conclusions:
- JSB1 antibody detects PGP in a majority of laryngeal squamous cell carcinomas.
- The expression of PGP by JSB1 does not appear to correlate with key clinicopathological parameters in this cohort.
- Discrepancies in results between JSB1 and C219 antibodies highlight the complexity of PGP detection and its clinical relevance in laryngeal cancer.
